, Tracking Stock Market Picks
Enter Symbol:
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

down 20.10 %

Achillion Pharmaceuticals, Inc. (ACHN) rated Buy with price target $12 by Deutsche Bank

Posted on: Wednesday,  Sep 19, 2012  2:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 09/19/2012, when the stock price was $9.40. Since
then, Achillion Pharmaceuticals, Inc. has lost 20.11% as of 10/07/2015's recent price of $7.51.
If you would have followed this Deutsche Bank's recommendation on ACHN, you would have lost 20.1% of your investment in 1113 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/19/2012 2:25 PM Buy
9.40 12.00
as of 12/31/2012
1 Week down  -7.18 %
1 Month up  2.82 %
3 Months down  -22.98 %
1 YTD down  -14.78 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy